Natco Pharma reported a more than 39% decline in consolidated net profit to ₹63.40 crore for the quarter ended December, in the face of lower sales and realisation from key products.
Revenue declined almost 25% to ₹386 crore.
The decline in revenue and profits was due to lower sales in domestic oncology and weak realisation of profits from anti-viral oseltamivir (generic of Tamiflu) in the U.S., the company said on Thursday.
The firm declared a third interim dividend of ₹1 per equity share.
In terms of contribution to revenue, share of formulations exports, including profit share and foreign subsidiaries, was the highest at ₹162.1 crore, followed by APIs at ₹97.8 crore and formulations for the domestic market at ₹95.3 crore. Other income of ₹24.9 crore and other operating income of ₹5.9 crore made up the rest of the revenue.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
